Navigation Links
Market for Biologic Imaging Reagents and Medical Imaging & Diagnosing Analyzed in New Research Reports at ReportsnReports.com
Date:1/7/2013

Dallas, Texas (PRWEB) January 07, 2013

Biologic imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as X-ray, computer tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology permits imaging at the cellular and molecular level, paving the way for earlier diagnosis and treatment of diseases. Biologic imaging reagents play a critical role in this medical revolution.

At the same time, ongoing advances in genomics, proteomics and cellular analysis are aided by imaging technologies, including fluorescent dyes and probes, quantum dot nanoparticles, and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing and polymerase chain reaction (PCR) relies on sensitive biologic fluorescent imaging reagents.

Advances in technologies that are used in biologic imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biologic targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biologic imaging industry by enabling novel imaging reagents and unique market opportunities. The report “Biologic Imaging Reagents: Technologies and Global Markets” analyzes these developments and their impact on the future markets for biologic imaging reagents.

Given these market and technology dynamics, it is especially timely to examine t
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM360
2. LA Dental Bone Graft Substitute & Other Biomaterials Market Reviewed in New iData Research Report Available at MarketPublishers.com
3. Growing Job-Market Niche Inside The Economic Decline: A Wysebridge Review
4. Lucintel’s Analysis of the Global Glass Mat Thermoplastics Industry: Market is Expected to Reach US $481 Million in 2017
5. Lucintel’s Analysis of Growth Opportunities in China’s Composites Industry: Expect Market to Surpass $11 Billion in 2017
6. Asia-Pacific Active Pharmaceutical Ingredients (APIs) Market Analysis & Forecasts to 2017 in New Research Report @ RnRMarketResearch.com
7. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
8. Europe Anesthesia and Respiratory Devices Market Outlook to 2018 - Respiratory Devices, Respiratory Measurement Devices, Anesthesia Machines, Sleep Apnea Diagnostic Systems, Pain Management Devices and Others
9. Accelr8 Announces NASDAQ Capital Market Listing
10. Monoclonal Antibody Partnering Terms & Agreements Discussed in New Report Now Available at MarketPublishers.com
11. Scientific Research & Development in the US Industry Market Research Report from IBISWorld has Been Updated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... patented university inventions licensed to biotechnology firms has ... To open these roadblocks, the researchers suggest that ... discovery stage could lead to faster commercialization down ... from discoveries made in university laboratories and licensed ... clinical trials, which have a high failure rate. ...
(Date:8/20/2014)... August 20, 2014 High performance ... apply the most complete climate and Earth system ... climate change issues. , Eight national laboratories, including ... the National Center for Atmospheric Research, four academic ... effort. Other participating national laboratories include Argonne, Brookhaven, ...
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... the enterprise replication cluster, faster loading speeds, higher ... Elasticsearch. This release happens to coincide with a ... GraphDB™ was formerly known as OWLIM. ... enterprise resilient RDF triplestore will also benefit from ...
Breaking Biology Technology:Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who have ... rituximab-containing,regimen. According to the National Cancer Institute, an ...
... MYL ) today,announced that Mylan Pharmaceuticals Inc. ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Balsalazide Disodium Capsules are the generic version of ... approximately,$130.9 million for the 12 months ending Sept. ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... -- When are athletes who have suffered concussions ready ... study has found that high school athletes who head ... days experience a significant regression in their abilities to ... regression, as seen in changes in their balance and/or ... athletes. Ten of the 12 had returned to activity ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... searches blood for the tiniest remnants of broken down ... up cancer activators called proteases. The results improve researchers, ... to where to look for possible indicators of early ... , the research shows previously unknown contributing factors to ...
... The cells and tissues in our bodies grow, develop ... the various microbial pathogens that invade our bodies and ... milieu. Yet the methods of culturing and studying human ... on flat impermeable surfaces. While such 2-D culturing and ...
... with a peer facing the same self-management challenges helped ... sugar levels better than those who used traditional nurse ... University of Michigan Health System. The findings, published ... showed the peer partner program resulted in lower ...
Cached Biology News:New clues to how cancer-related proteins plasmin, thrombin lose inhibition 2New clues to how cancer-related proteins plasmin, thrombin lose inhibition 3New clues to how cancer-related proteins plasmin, thrombin lose inhibition 4The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4Diabetic adults' conditions improved after phone calls with fellow patients 2Diabetic adults' conditions improved after phone calls with fellow patients 3